Company formed to advance SYN-001, an FDA-designated orphan and rare pediatric disease therapeutic candidate acquired from Nobias Therapeutics Phase IIb trial planned to further evaluate SYN-001 for the treatment of neuropsychiatric symptoms associated with 22q11.2 Deletion Syndrome (22q11DS) JULY 23, 2026 -- A consortium of European and US-based investors and Nobias Therapeutics today announced the launch of Synaptiq Therapeutics, a privately held, clinical-stage biotechnology company dedicate

Financing led by Frazier Life Sciences with participation from Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, Trails Edge Capital Partners, Pivotal bioVenture Partners and KCap Biotechnology Fund and all existing investors Proceeds to support ongoing late-stage global clinical development and commercialization preparation of dotinurad, a next-generation, once daily, oral URAT1 inhibitor with the potential to deliver best-in-class safety and efficac

Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2. Consistent with previously reported results3, the publication highlights TLX591-Tx’s clinical differentiation and safety profile. TLX591-Tx, Telix’s lead PSMA-targeting rADC therapy candidate, is currently being evaluated in ProstACT Global Phase 3 study4 for advanced metastatic prostate cancer. July 22, 2026 -- Teli

July 22, 2026 -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that it has initiated the rolling submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for ALXN1840 (tiomolibdate choline, TMC), its first-in-class albumin tripartite complex (“ATC”) activator for the treatment of Wilson disease. The FDA ha

- PDUFA target action date of May 8, 2027 - If approved, encaleret will be the first and only approved therapy specifically indicated for individuals living with ADH1, representing a potential blockbuster opportunity for BridgeBio- Encaleret demonstrated consistent efficacy across all pre-specified primary and key secondary efficacy endpoints normalizing key markers of CaSR-driven disease biologywithout the need for calcium and vitamin D supplements, with a favorable safety and tolerability prof

Financing will support development of RN-014 and RN-032 and continued expansion of the company's kidney disease pipeline July 21, 2026 -- Rege Nephro Co., Ltd. ("Rege Nephro"), a clinical-stage biotechnology company focused on iPS cell-based kidney regenerative medicine and drug discovery, today announced the closing of a financing round totaling approximately US$10.6 million through the issuance of J-KISS (Japan-Keep It Simple Security) share acquisition rights. The proceeds are expected to su

July 20, 2026 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been dosed in a Phase II clinical study (AK146D1-201) evaluating its internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate (ADC), AK146D1, in combination with ivonescimab (the Company's PD-1/VEGF bispecific antibody) in patients with advanced non-small cell lung cancer (NSCLC). The study will explore the therapeutic potential of this combination, with a particular emphasi

IM-3050 is a fibroblast activation protein (FAP)-targeted radioligand therapy designed to deliver radioactive lutetium-177 directly to FAP-expressing cells. The Phase 1 trial is designed to evaluate the safety, tolerability, dosimetry, pharmacokinetics, and preliminary anti-tumor activity of IM-3050 in participants with FAP-expressing advanced solid tumors. Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies,

This Tamgiblimab Biologics Sequence Review Report was produced with PatSnap Biology Modality MCP workflows. It connects patent-scale similarity search, sequence retrieval, pairwise alignment and antibody–antigen evidence in a reproducible screen. Explore the PatSnap MCP servers used in this report. Review date: 23 July 2026. This report supports R&D and IP triage; it is not a legal opinion, freedom-to-operate conclusion or validity analysis. A sequence hit does not establish infringement.

This Sotevtamab Biologics Sequence Review Report was produced with PatSnap Biology Modality MCP workflows. It connects patent-scale similarity search, sequence retrieval, pairwise alignment and antibody–antigen evidence in a reproducible screen. Explore the PatSnap MCP servers used in this report. Review date: 23 July 2026. This report supports R&D and IP triage; it is not a legal opinion, freedom-to-operate conclusion or validity analysis. A sequence hit does not establish infringement.